About Your Peptide Tracker
Your Peptide Tracker is for readers trying to understand research on semaglutide, retatrutide, MOTS-c, and KPV. A search for a peptide tracker often means a search for an app. This site offers no app, dose tracking, or personal log. It follows studies and safety reports about the four peptides.
The pages are intended to make research easier to read without making its conclusions broader. They explain technical terms in context, link claims to sources, and keep observations separate from treatment advice. No article can evaluate an individual health history or choose a medicine for a reader.
What the site follows

The four peptides occupy different places in the evidence. Semaglutide has large randomized trials and approved manufactured medicines. Retatrutide has published human trials while remaining investigational. KPV research is largely preclinical, meaning it comes before established treatment evidence in people. MOTS-c research includes laboratory experiments and measurements of the peptide naturally present in the body.
Those differences shape the pages. A single list of benefits would hide whether a result came from a person, a mouse, or a cell culture. Each compound article identifies the setting of its main studies, explains what researchers measured, and describes the limitations that affect interpretation.
The comparison article brings these distinctions together. It does not choose a best peptide or assign scores. It explains why weight change, a blood marker, and a clinical event require different kinds of evidence before they can support a health claim.
How findings are described
A study result belongs with its participants and follow-up period. For example, the SELECT cardiovascular trial enrolled people with established cardiovascular disease and excess weight, without diabetes. Its findings address that setting. Removing the population would make the statement easier to read but less accurate.
The same care applies to a statistical estimate. A relative reduction and an absolute difference describe different aspects of a result. When a percentage is central to a page, the comparison group and analysis need to remain visible. A group average is not presented as an expected outcome for a particular reader.
Animal and cell findings are described as such. A preparation with a targeted carrier is not reduced to an ingredient name. Observational studies are not described as if researchers assigned treatment. A source that proposes a mechanism is used to explain the mechanism, rather than to establish a clinical effect it did not measure.
Safety and regulatory information
Safety can mean documented unwanted effects, a possible risk, or missing information. These are different statements. A trial that records nausea supplies evidence of an observed effect. A regulatory review that raises an immune-reaction concern without human data supplies a risk assessment, not a measured event rate.
The articles aim to make that difference visible. They avoid treating a short adverse-effect list as proof of safety when human studies are absent. They also distinguish the naturally occurring peptide in a blood sample from a preparation administered as treatment.
Regulatory passages identify the relevant agency and date. A draft enforcement policy is described as a draft, and approval of a manufactured medicine is not extended to a compounded preparation. The reference list includes the policy documents cited alongside the scientific literature so readers can tell which kind of question each source addresses.
Reading without a personal treatment plan
The site gives no medical advice and provides no dose selection, cycle design, or mixing directions. It does not collect a personal treatment history for review. A clinician's conversation with a patient includes symptoms, other medicines, diagnoses, examination, and follow-up that a general article cannot supply.
Readers can use the pages to identify a paper, understand its main question, and recognize what remains unknown. An article may help frame a discussion, but it cannot decide whether someone's situation matches a trial or whether a requested treatment is appropriate.
The contact information is for article and source corrections. A precise note about an omitted limitation or a mistaken population can improve a page. There is no need to include private health details to explain an error in the research description. The questions page gives further examples of how to distinguish tracking research from tracking treatment.